Open Access

Efficacies of rosiglitazone and retinoin on bleomycin‑induced pulmonary fibrosis in rats

  • Authors:
    • Wencheng Yu
    • Liyun Mi
    • Teng Long
  • View Affiliations

  • Published online on: June 7, 2017     https://doi.org/10.3892/etm.2017.4555
  • Pages: 609-615
  • Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study investigated the intervention efficacies of rosiglitazone (ROS) and retinoin (RET) on bleomycin‑induced pulmonary fibrosis in rats. A total of 48 rats were randomly divided into the control group (group C), the model group (group M), the dexamethasone group (group D), the ROS group (group R), the RET group (group W) and the ROS + RET group (group L). Group M and the treatment groups were intratracheally injected with 5 mg/kg bleomycin, while group C was injected with saline. The lungs of rats in each group were inspected using high resolution computed tomography (HRCT), lung tissue hematoxylin and eosin staining and Masson staining; furthermore, lung L‑hydroxyproline (Hyp) content and the concentration of transforming growth factor β1 (TGF‑β1) serum of each group were also determined. The fibrosis score, Hyp content and TGF‑β1 concentration of each treatment group were significantly lower when compared with group M (P<0.01), while the imaging results were improved when compared with group M, with lower alveolitis and fibrosis scores. Group L, R and W exhibited significantly lower fibrosis scores, Hyp content and TGF‑β1 concentrations when compared with group D (P<0.05). Imaging results for group L, R and W indicated that while the imaging results were superior to group D, group L was lower than groups R and W (P<0.05). No significant difference in the fibrosis score, Hyp content and TGF‑β1 concentration was exhibited between groups R and W (P>0.05). Findings from the present study conclude that ROS and RET are able to suppress bleomycin‑induced pulmonary fibrosis with improved efficacies when compared with dexamethasone; furthermore, the combination of these two pharmacological agents may exert synergistic effects.
View Figures
View References

Related Articles

Journal Cover

July-2017
Volume 14 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yu W, Mi L and Long T: Efficacies of rosiglitazone and retinoin on bleomycin‑induced pulmonary fibrosis in rats. Exp Ther Med 14: 609-615, 2017
APA
Yu, W., Mi, L., & Long, T. (2017). Efficacies of rosiglitazone and retinoin on bleomycin‑induced pulmonary fibrosis in rats. Experimental and Therapeutic Medicine, 14, 609-615. https://doi.org/10.3892/etm.2017.4555
MLA
Yu, W., Mi, L., Long, T."Efficacies of rosiglitazone and retinoin on bleomycin‑induced pulmonary fibrosis in rats". Experimental and Therapeutic Medicine 14.1 (2017): 609-615.
Chicago
Yu, W., Mi, L., Long, T."Efficacies of rosiglitazone and retinoin on bleomycin‑induced pulmonary fibrosis in rats". Experimental and Therapeutic Medicine 14, no. 1 (2017): 609-615. https://doi.org/10.3892/etm.2017.4555